The mechanisms of acute interstitial nephritis in the era of immune checkpoint inhibitors in melanoma.
acute interstitial nephritis
immunotherapy
melanoma
nephrotoxicity
Journal
Therapeutic advances in medical oncology
ISSN: 1758-8340
Titre abrégé: Ther Adv Med Oncol
Pays: England
ID NLM: 101510808
Informations de publication
Date de publication:
2019
2019
Historique:
received:
15
11
2018
accepted:
21
08
2019
entrez:
4
10
2019
pubmed:
4
10
2019
medline:
4
10
2019
Statut:
epublish
Résumé
Treatment with immune checkpoint inhibitors (ICIs) has improved the prognosis of patients with a number of types of cancer, but the frequent development of immune-related adverse effects (irAEs) can worsen the outcome. The most common irAEs involve the gastrointestinal, cutaneous, and endocrine systems, but nephrotoxicity, resulting from damage to the tubule-interstitial compartment, may occur in some patients. The early phases of acute interstitial nephritis (AIN) are characterized by systemic symptoms that indicate a poor clinical state as well as a mild deterioration of renal function. Tubular injury is due to a direct effect mediated by cytotoxic CD8
Identifiants
pubmed: 31579108
doi: 10.1177/1758835919875549
pii: 10.1177_1758835919875549
pmc: PMC6759704
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
1758835919875549Commentaires et corrections
Type : ErratumIn
Informations de copyright
© The Author(s), 2019.
Déclaration de conflit d'intérêts
Conflict of interest statement: The authors declare that there is no conflict of interest.
Références
Arthritis Rheum. 2008 Jan;58(1):251-62
pubmed: 18163476
Semin Cancer Biol. 2018 Oct;52(Pt 2):207-215
pubmed: 28917578
Lancet. 2018 Jan 27;391(10118):305-306
pubmed: 29413038
Anticancer Res. 2012 Oct;32(10):4607-8
pubmed: 23060594
Presse Med. 1988 Feb 13;17(5):201-5
pubmed: 2965376
Cancer Treat Rev. 2016 Mar;44:51-60
pubmed: 26874776
Br J Cancer. 2019 Jan;120(1):3-5
pubmed: 30413824
J Clin Oncol. 2013 Feb 10;31(5):616-22
pubmed: 23295794
Adv Chronic Kidney Dis. 2017 Mar;24(2):64-71
pubmed: 28284381
J Clin Oncol. 2017 Dec 1;35(34):3815-3822
pubmed: 28915085
N Engl J Med. 1984 Mar 1;310(9):563-72
pubmed: 6363936
Clin Kidney J. 2013 Feb;6(1):8-14
pubmed: 27818745
Kidney Int. 1989 May;35(5):1257-70
pubmed: 2770107
N Engl J Med. 2010 Aug 19;363(8):711-23
pubmed: 20525992
Oncotarget. 2017 Oct 31;8(62):106132-106142
pubmed: 29285320
Am J Pathol. 2016 Dec;186(12):3225-3235
pubmed: 27750046
Am J Kidney Dis. 2016 Aug;68(2):287-291
pubmed: 27113507
Exp Cell Res. 2017 Sep 15;358(2):260-268
pubmed: 28669663
Curr Oncol Rep. 2018 Mar 3;20(2):22
pubmed: 29502288
J Immunother Cancer. 2018 May 16;6(1):39
pubmed: 29769148
BMC Nephrol. 2018 Jul 3;19(1):156
pubmed: 29970032
Clin Nephrol. 2008 Oct;70(4):271-83
pubmed: 18826852
J Clin Oncol. 2018 Jun 10;36(17):1714-1768
pubmed: 29442540
Lancet. 2014 Sep 20;384(9948):1109-17
pubmed: 25034862
Nephrol Dial Transplant. 2007 Jun;22(6):1527-36
pubmed: 17339272
Am J Nephrol. 2017;45(2):160-169
pubmed: 28076863
Nat Rev Immunol. 2013 Dec;13(12):844-5
pubmed: 24136622
N Engl J Med. 2015 Jan 22;372(4):320-30
pubmed: 25399552
N Engl J Med. 2016 Nov 03;375(18):1749-1755
pubmed: 27806233
Eur J Cancer. 2016 Feb;54:139-148
pubmed: 26765102
Expert Rev Clin Immunol. 2016;12(1):79-89
pubmed: 26505837
Nephrol Dial Transplant. 2004 Nov;19(11):2778-83
pubmed: 15340098
Oncoimmunology. 2017 Nov 6;7(2):e1387706
pubmed: 29308314
Cancer Treat Rev. 2018 Feb;63:116-121
pubmed: 29276997
Immunity. 1999 Aug;11(2):141-51
pubmed: 10485649
Lancet Oncol. 2016 Oct;17(10):1374-1385
pubmed: 27592805
Invest New Drugs. 2014 Aug;32(4):769-73
pubmed: 24687600
Ann Oncol. 2018 Oct 1;29(Suppl 4):iv264-iv266
pubmed: 29917046
J Immunol. 2015 Jan 1;194(1):325-33
pubmed: 25404361
Cancer. 2013 May 1;119(9):1675-82
pubmed: 23400564
Clin Nephrol. 2014 Sep;82(3):149-62
pubmed: 25079860
Crit Care Clin. 2015 Oct;31(4):621-32
pubmed: 26410133
Histopathology. 2017 Jan;70(1):94-108
pubmed: 27960238
Kidney Int. 2010 Nov;78(10):951-3
pubmed: 21030970
Kidney Int. 2008 Apr;73(8):940-6
pubmed: 18185501
Nat Commun. 2016 Feb 02;7:10391
pubmed: 26837003
Cancer Treat Rev. 2018 Sep;69:21-28
pubmed: 29864718
J Bone Miner Res. 2014 Jan;29(1):55-66
pubmed: 23787729
Kidney Int. 2001 Aug;60(2):804-17
pubmed: 11473672
Am J Transplant. 2014 Sep;14(9):1985-91
pubmed: 25098238
Science. 2018 Jan 5;359(6371):104-108
pubmed: 29302014
Immunotherapy. 2018 Feb;10(2):93-105
pubmed: 29145737
Clin Cancer Res. 2016 Feb 15;22(4):886-94
pubmed: 26446948
Oncology (Williston Park). 2018 Jul 15;32(7):351-9
pubmed: 30080920
Science. 2018 Jan 5;359(6371):97-103
pubmed: 29097493
Lancet Oncol. 2010 Feb;11(2):155-64
pubmed: 20004617
Clin Cancer Res. 2017 Apr 15;23(8):1920-1928
pubmed: 27827313
Oncol Lett. 2017 Nov;14(5):5671-5680
pubmed: 29113194
Am J Ther. 2015 May-Jun;22(3):e84-7
pubmed: 24067875
J Immunother Cancer. 2017 Nov 21;5(1):95
pubmed: 29162153
Trends Immunol. 2015 Dec;36(12):763-777
pubmed: 26572555
Ann Oncol. 2017 Jul 1;28(7):1484-1494
pubmed: 28383639
Immunol Rev. 2010 Jul;236:219-42
pubmed: 20636820
J Urol. 2018 Jan;199(1):161-171
pubmed: 28797714
Ann Oncol. 2016 Apr;27(4):559-74
pubmed: 26715621
Kidney Int. 2016 Sep;90(3):638-47
pubmed: 27282937
Science. 2018 Jan 5;359(6371):91-97
pubmed: 29097494
Ren Fail. 1998 Nov;20(6):809-19
pubmed: 9834979
J Clin Invest. 2018 Feb 1;128(2):715-720
pubmed: 29309048
Kidney Int. 2016 Sep;90(3):474-6
pubmed: 27521108
Expert Rev Clin Immunol. 2014 Oct;10(10):1395-404
pubmed: 25225774
Kidney Int. 2015 May;87(5):909-17
pubmed: 25671763
Science. 2018 Mar 23;359(6382):1350-1355
pubmed: 29567705
Nephrol Dial Transplant. 2013 Oct;28(10):2502-9
pubmed: 24009289
CA Cancer J Clin. 2017 Jan;67(1):7-30
pubmed: 28055103
J Am Soc Nephrol. 2018 Aug;29(8):2039-2052
pubmed: 29959196
Nat Rev Immunol. 2018 Mar;18(3):153-167
pubmed: 28990585
N Engl J Med. 2017 Jun 8;376(23):2304
pubmed: 28591526
Semin Nephrol. 1995 May;15(3):228-35
pubmed: 7631049
N Engl J Med. 2009 Jul 9;361(2):211-2
pubmed: 19587352